This interesting article details how in the last round of investors VIVEbiotech has captured 3.5 million euros from current shareholders and two venture capital funds, Easo Ventures and Inveready, with an additional million from CDTI (Center for Industrial Technological Development of the Spanish Government).

As noted by Dr. Gurutz Linasasoro, CEO of VIVEbiotech, “thanks to this successful capitalization we can undertake our expansion to meet the demands of our customers and a growing market.” Dr. Linazasoro pointed out that investments like this are essential for the consolidation and take-off phases of biotechs.

In addition to VIVEbiotech, this article also reflects recent actions of other companies located in Gipuzkoa such as the agreement carried out between the Mondragón Corporation and Grifols, and the sustained commitment of Straumann to be located in Mendaro.

Thanks to the shareholders, Easo Ventures, Inveready and the CDTI for their contributions that will allow us to move forward with this exciting project.

The article can be read here: